Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Tolerability Study of High-Dose PURETHAL Mites in Allergic Rhinitis/Rhinoconjunctivitis
2008-006261-81Phase 2Completed
- Sponsor
- HAL Allergy Group
- Start
- Mar 2009
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Purethal in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and asthma, sponsored by HAL Allergy Group. Primary endpoint: Early local reactions (ELR) 15 minutes post-injection. Started Mar 2009; status: completed.
02
Drugs
Purethal
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)asthma
Beyond the preview
Go deeper on 2008-006261-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006261-81.